Investing

The company said it plans to expand U.S. access to its services while growing its pipeline to include additional cardiac conditions and new distribution channels.

The company, which uses AI to help companies manage value-based care contracts, will use the funds to grow its team and scale its platform.

The funding comes a year after the company secured $70 million in a Series B funding round.

Also, OMRON in Singapore has launched a new medical device plan featuring AI-driven recommendations for self-management of chronic diseases.

When it comes to making strategic AI investment deals, companies need to articulate their competitive advantage and how they view the market around them, says Jason Smith, venture acceleration fellow at MATTER.

The oncology-focused company will use the funds to boost manufacturing capacity, grow its commercial team and develop its next-generation Amma product.

The funds will be used to expand the company's enterprise-grade platform, aiOS, and accelerate the development of CARE, a clinical-grade foundation model.

The Australian company offers its members access to AI agents that analyze their health data, lifelong health plans, whole-body testing and a personal doctor.

The funds will be used to grow the company's engineering and commercial workforce, enhance product development, and accelerate integration with payers and providers.

The funds will be used to improve the company's flight cadence and expand its pharmaceutical lab capabilities.